Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$3.99M-19.93%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Matthew W. Foehr
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 89
- Beta
- 1.05
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 8.68
Financials
Revenue
$3.99M-19.9%Net Income
$-15.73MEBITDA
$-12.24MFree Cash Flow
$10.57M+581.8%EPS (diluted)
$-0.12Shares Outstanding (diluted)
129.29M+12.6%Operating Expenses
$16.80MCash & Debt
$64.21MRevenue by Segment (annual)
$8.14MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $18.67M | $-64.78M | $-0.57 |
| 2024 | $26.39M | $-62.03M | $-0.61 |
| 2023 | $34.16M | $-50.62M | $-0.51 |
| 2022 | $59.08M | $-22.33M | $-0.26 |
| 2021 | $34.75M | $-27.04M | $-0.24 |
| 2020 | $23.27M | $-17.56M | $-0.15 |
| 2019 | $18.32M | $-13.59M | $-0.12 |
Valuation
OABIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
35-67.19%Social Signal Score
Mentions (12)
- Newsseekingalpha.com·22d ago·Negative
…Partner Programs OmniAb has reached self-sustaining cash flow, no longer requiring investor funding to operate, with 2026 projected as break-even for net cash usage. OABI's portfolio model offers contractually protected options on hundreds of programs, with over $3 billion in potential milestones and average royalty rates around 3.4%. The Lilly ion channel partnership and a robust late-stage pipeline signal validation and near-term catalysts, including up to 19 clinical trial readouts through 20…
View source ↗ - Newsseekingalpha.com·23d ago·Positive
OmniAb, Inc. (OABI) Q3 2026 Earnings Call Transcript OmniAb, Inc. (OABI) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·23d ago·Neutral
OmniAb Q3 Earnings Call Highlights OmniAb NASDAQ: OABI reported higher third-quarter revenue and raised its full-year 2026 revenue and year-end cash outlook, citing partner-program milestones, expanding service revenue and early commercial progress for its xPloration B-cell screening platform.
View source ↗ - Newszacks.com·23d ago·Negative
OmniAb, Inc. (OABI) Reports Q3 Loss, Tops Revenue Estimates OmniAb, Inc. (OABI) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.14 per share a year ago.
View source ↗ - Newsbusinesswire.com·23d ago·Positive
OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today reported financial results for the three and nine months ended September 30, 2026, provided operating and partner program progress, and updated 2026 financial guidance. “Our strong third-quarter 2026 performance reflects o…
View source ↗ - Newsmarketbeat.com·28d ago·Negative
OmniAb Highlights $3B Milestone Pipeline, AI Antibody Platform at Conference OmniAb NASDAQ: OABI Chief Financial Officer Kurt Gustafson outlined the company's antibody-discovery platform, partner pipeline and revenue model during a company presentation, emphasizing a strategy built around licensing technology to pharmaceutical and biotechnology companies rather than developing drugs internally.
View source ↗ - Newsmarketbeat.com·46d ago·Negative
OmniAb Investor Day Spotlights Royalty Pipeline, OmniTides Launch and xPloration Growth OmniAb NASDAQ: OABI used its investor and analyst day to outline its strategy for expanding royalty-bearing partnerships, commercializing its xPloration screening platform and entering the peptide-discovery market through its newly introduced OmniTides platform.
View source ↗ - Newsseekingalpha.com·47d ago·Positive
OmniAb, Inc. (OABI) Analyst/Investor Day Transcript OmniAb, Inc. (OABI) Analyst/Investor Day Transcript
View source ↗ - Newszacks.com·47d ago·Positive
All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to Buy OmniAb, Inc. (OABI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newsseekingalpha.com·96d ago·Negative
…is Early-Stage Biotech OmniAb is transitioning from early-stage biotech to a scalable platform, driven by milestone-rich partnerships like the recent Eli Lilly deal. OABI's 110 partners and 425 programs are generating higher, more predictable milestone revenues, with $340M in clinical-stage milestone potential and a $3B+ total milestone pool. The Lilly collaboration validates OABI's technology, offers high-margin, capital-light economics, and has directly improved 2026 cash guidance to $49–$53M.
View source ↗ - Newsbusinesswire.com·97d ago·Neutral
OmniAb Raises 2026 Financial Guidance EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today raised its 2026 cash and cash equivalents financial guidance following recent technology licensing activity. “Recent business development and licensing activity has enabled us to again raise our 2026 financial guidance and significantly increase our cash outlo…
View source ↗ - Newsbusinesswire.com·97d ago·Neutral
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company EMERYVILLE, Calif.--(BUSINESS WIRE)---- $OABI #OABI--OmniAb, Inc. (NASDAQ: OABI), a provider of cutting-edge discovery research technology to enable the discovery of next-generation therapeutics, today announced a global collaboration and license agreement with Eli Lilly and Company (Lilly) for a new ion channel program. The collaboration leverages OmniAb's technology platform and experti…
View source ↗
Earnings
Wed, Mar 3(in 3 months)
Consensus estimate $-0.12 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Oct 30$-0.12 vs $-0.13beat
- Thu, Aug 6$-0.05 vs $-0.12beat
- Thu, May 7$-0.06 vs $-0.10beat
- Wed, Mar 4$-0.11 vs $-0.08miss
- Tue, Nov 4$-0.14 vs $-0.14miss
- Wed, Aug 6$-0.15 vs $-0.14miss
Estimates and results for OABI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OABI officers and directors.
- Bought
- $108k
- Sold
- $283k
2 trades
12 trades
- Foehr Matthew Wsold
- Gustafson Kurt Asold
- Berkman Charles Ssold
- Berkman Charles Ssold
- Gustafson Kurt Asold
- Foehr Matthew Wsold
- Foehr Matthew Wsold
- Gustafson Kurt Asold
86 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in OABI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
